S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
66,000% upside on tiny biotech? (Ad)
US, UK navies say they responded to distress call as Iran's Revolutionary Guard 'harassed' ship
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
WARNING TO ALL U.S. INVESTORS (Ad)
Greek authorities rescue 91 migrants from river islet on border with Turkey
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
WARNING TO ALL U.S. INVESTORS (Ad)
Stock market today: Asian stocks follow Wall St up after strong US jobs report
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
66,000% upside on tiny biotech? (Ad)
US, UK navies say they responded to distress call as Iran's Revolutionary Guard 'harassed' ship
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
WARNING TO ALL U.S. INVESTORS (Ad)
Greek authorities rescue 91 migrants from river islet on border with Turkey
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
WARNING TO ALL U.S. INVESTORS (Ad)
Stock market today: Asian stocks follow Wall St up after strong US jobs report
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
66,000% upside on tiny biotech? (Ad)
US, UK navies say they responded to distress call as Iran's Revolutionary Guard 'harassed' ship
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
WARNING TO ALL U.S. INVESTORS (Ad)
Greek authorities rescue 91 migrants from river islet on border with Turkey
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
WARNING TO ALL U.S. INVESTORS (Ad)
Stock market today: Asian stocks follow Wall St up after strong US jobs report
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
66,000% upside on tiny biotech? (Ad)
US, UK navies say they responded to distress call as Iran's Revolutionary Guard 'harassed' ship
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
WARNING TO ALL U.S. INVESTORS (Ad)
Greek authorities rescue 91 migrants from river islet on border with Turkey
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
WARNING TO ALL U.S. INVESTORS (Ad)
Stock market today: Asian stocks follow Wall St up after strong US jobs report
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024

Rocket Pharmaceuticals (RCKT) Stock Forecast, Price & News

$21.84
+0.91 (+4.35%)
(As of 06/2/2023 08:48 PM ET)
Compare
Today's Range
$21.07
$21.88
50-Day Range
$15.79
$22.24
52-Week Range
$9.50
$23.48
Volume
602,600 shs
Average Volume
790,099 shs
Market Capitalization
$1.76 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.09

Rocket Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
133.9% Upside
$51.09 Price Target
Short Interest
Bearish
10.07% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
0.16mentions of Rocket Pharmaceuticals in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$43,678 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.08) to ($2.12) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Medical Sector

225th out of 980 stocks

Pharmaceutical Preparations Industry

103rd out of 485 stocks


RCKT stock logo

About Rocket Pharmaceuticals (NASDAQ:RCKT) Stock

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RCKT Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
See More Headlines

RCKT Price History

RCKT Company Calendar

Last Earnings
5/04/2023
Today
6/04/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RCKT
Employees
151
Year Founded
2018

Price Target and Rating

Average Stock Price Forecast
$51.09
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+133.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
12 Analysts

Profitability

Net Income
$-221,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.70 per share

Miscellaneous

Free Float
53,370,000
Market Cap
$1.76 billion
Optionable
Optionable
Beta
1.22

Social Links


Key Executives

  • Gaurav D. ShahGaurav D. Shah
    Chief Executive Officer & Director
  • Kinnari Patel
    President & Chief Operating Officer
  • John C. Militello
    Treasurer, Chief Financial & Accounting Officer
  • Mayo Pujols
    Chief Technical Officer & Executive Vice President
  • Mark White
    Chief Medical Officer













RCKT Stock - Frequently Asked Questions

Should I buy or sell Rocket Pharmaceuticals stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last twelve months. There are currently 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RCKT shares.
View RCKT analyst ratings
or view top-rated stocks.

What is Rocket Pharmaceuticals' stock price forecast for 2023?

12 equities research analysts have issued 12-month price objectives for Rocket Pharmaceuticals' stock. Their RCKT share price forecasts range from $34.00 to $75.00. On average, they anticipate the company's stock price to reach $51.09 in the next year. This suggests a possible upside of 133.9% from the stock's current price.
View analysts price targets for RCKT
or view top-rated stocks among Wall Street analysts.

How have RCKT shares performed in 2023?

Rocket Pharmaceuticals' stock was trading at $19.57 on January 1st, 2023. Since then, RCKT shares have increased by 11.6% and is now trading at $21.84.
View the best growth stocks for 2023 here
.

When is Rocket Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our RCKT earnings forecast
.

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) released its quarterly earnings data on Thursday, May, 4th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.11. During the same period in the prior year, the firm posted ($0.67) earnings per share.

What other stocks do shareholders of Rocket Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA).

What is Rocket Pharmaceuticals' stock symbol?

Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."

Who are Rocket Pharmaceuticals' major shareholders?

Rocket Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.79%), Maverick Capital Ltd. (5.48%), Wellington Management Group LLP (5.11%), State Street Corp (5.00%), Westfield Capital Management Co. LP (4.02%) and Price T Rowe Associates Inc. MD (2.32%). Insiders that own company stock include Gaurav Shah, Gotham Makker, John Militello, Jonathan David Schwartz, Kinnari Patel and Rtw Investments, Lp.
View institutional ownership trends
.

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rocket Pharmaceuticals' stock price today?

One share of RCKT stock can currently be purchased for approximately $21.84.

How much money does Rocket Pharmaceuticals make?

Rocket Pharmaceuticals (NASDAQ:RCKT) has a market capitalization of $1.76 billion. The biotechnology company earns $-221,860,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis.

How many employees does Rocket Pharmaceuticals have?

The company employs 151 workers across the globe.

How can I contact Rocket Pharmaceuticals?

Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The official website for the company is www.rocketpharma.com. The biotechnology company can be reached via phone at (609) 659-8001, via email at investors@rocketpharma.com, or via fax at 646-224-9585.

This page (NASDAQ:RCKT) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -